4. CLINICAL PARTICULARS

4.1 Therapeutic indications
1. For relief of inflammation and pain in the following disorders and symptoms:
   Rheumatoid arthritis, osteoarthritis, lower back pain, periarthitis of the shoulder, and shoulder-arm-neck syndrome, toothache
2. For relief of postoperative, post-traumatic or post-exodontial pain and inflammation
3. For antipyresis and relief of pain in the following disorder:
   Acute upper respiratory, tract inflammation, (including acute upper airway inflammation, accompanying acute bronchitis)

4.2 Posology and method of administration

Posology:
For indications (1 & 2) the usual adult dosage is 60 mg of loxoprofen sodium (as anhydride) orally three times a day.
For p.r.n. use, administer 60-120 mg once orally. The dosage may be adjusted according to the patient’s age and symptoms.
For indication (3) the usual adult dosage is 60 mg of loxoprofen sodium (as anhydride) p.r.n. once orally.

The dosage may be adjusted according to the patient’s age and symptoms. In principle, the recommended maximum daily dose of ROXONIN is twice daily administration, and the total daily dose should not exceed 180 mg/day.

Use of ROXONIN on an empty stomach should be avoided.

Use in the Elderly
In as much as adverse reactions are likely to occur in elderly patients, ROXONIN should be used with caution, e.g., starting at a low dose, while closely monitoring the patient’s condition (see “Important Precautions”).
4.4 Special warnings and precautions for use

1) Careful Administration (ROXONIN should be administered with caution in the following patients.)

   a) Patients with a history of peptic ulcers [since the use of ROXONIN may cause recurrence of ulceration.]
   b) Patients with peptic ulcer associated with chronic use of nonsteroidal anti-inflammatory-analgesic agents whose clinical condition requires long-term administration of ROXONIN and who are currently on misoprostol therapy [ROXONIN must be administered with care while closely monitoring the clinical condition of patients receiving this drug continuously, because peptic ulcers may be refractory to treatment with misoprostol, which is indicated for nonsteroidal antiinflammatory-analgesic drug-induced peptic ulceration.]
   c) Patients with or with a history of blood disorders [since adverse reactions such as hemolytic anemia are prone to occur.]
   d) Patients with or with a history of hepatic function disorders [because exacerbation or recurrence of the hepatic function disorders have been reported with the use of ROXONIN.]
   e) Patients with or with a history of renal impairment [since adverse reactions such as edema, proteinuria, serum creatinine elevation or hyperkalemia have been reported with the use of ROXONIN.]
   f) Patients with cardiac dysfunction [See “CONTRAINDICATIONS”]
   g) Patients with a history of hypersensitivity
   h) Patients with bronchial asthma [as the disease state may be exacerbated.]
   i) Patients with colitis ulcerative [as the disease state may be exacerbated.]
   j) Patients with Crohn’s disease [as the disease state may be exacerbated.]
   k) Elderly subjects [See “Use in the Elderly”.]

2) Important Precautions

   a) It is important to note that treatment with antiinflammatory-analgesic agents is a symptomatic treatment, not a causal treatment.
3) Other Precautions
   a) It has been reported that temporary sterility is observed in women receiving long-term NSAID therapy

4.5 Interaction with other medicinal products and other forms of interaction
1. Drug Interactions Precautions for co-administration (ROXONIN should be co-administered with care when administered with the following drugs).

See Table.

4.6 Pregnancy, Delivery and lactation

Pregnancy
• ROXONIN should be administered to women who are or are possibly pregnant only when the anticipated therapeutic benefits are considered to outweigh any potential risk. [The safety of this ROXONIN in these populations has not been established.]
• ROXONIN should not be used in women in the late stages of pregnancy. [Delayed parturition has been reported in an animal study (in rats).]
• Fetal arterial vasoconstriction has been reported in a study on rats receiving the drug in the late stages of gestation.

Lactation
• Administration of this drug to nursing mothers should be avoided. If administration of this drug is judged to be essential, nursing should be discontinued. [Preclinical studies have showed that loxoprofen is excreted into milk in rats.]

4.7 Effects on ability to drive and use machines
Some undesirable effects (e.g. dizziness or sleepiness), have been reported. To be safe, should be careful when driving and using machine.

4.8 Undesirable effects
(Including reports on adverse reactions the incidence of which cannot be calculated)
Adverse reactions to this drug were reported in 409 (3.03%) of 13,486 patients treated. The major adverse reactions reported were gastrointestinal symptoms (Stomach discomfort, abdominal pain,
### Signs, Symptoms, and Treatment

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Mechanism and Risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coumarin Anticoagulants (e.g., Warfarin)</td>
<td>The inhibitory effect of this drug on prostaglandin biosynthesis may lead to inhibition of platelet aggregation and to hypo-coagulation, thereby adding to the anticoagulant effects of these drugs.</td>
</tr>
<tr>
<td>Sulfonlurea hypoglycemic agents (e.g., Tolbutamide)</td>
<td>It is generally considered that co-administration of this drug, the protein-binding rate of which is as high as 97.0% as loxoprofen or 92.8% as its trans-OH form, results in increased plasma levels of active form of the concurrently administered hypoglycemic agent with a high protein-binding rate, to enhance the effect of the latter drug.</td>
</tr>
<tr>
<td>New quinolone antimicrobial agents (e.g., Enoxacin hydrate)</td>
<td>New quinolone antimicrobials inhibit receptor binding of GABA, an inhibitory neurotransmitter in the central nervous system, and hence may produce a convulsant effect. Co-administration with these drugs is thus considered to enhance their inhibitory effects.</td>
</tr>
</tbody>
</table>

### Nausea and/or vomiting, anorexia, etc.: 2.25%)

- Edema (0.59%); rash, urticaria, etc. (0.21%); and sleepiness (0.10%).

1) **Clinically significant adverse reactions** (incidence unknown)

1. **Shock and anaphylactoid symptoms**: Shock and anaphylactoid symptoms (decreased blood pressure, urticaria, edema of the larynx, dyspnea, etc.) have been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

2. **Hemolytic anemia, leukopenia, and thrombocytopenia**: Hemolytic anemia, leukopenia, and thrombocytopenia have been reported with the use of ROXONIN. Patients should be carefully followed by hematological examination, etc. during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

3. **Oculomucocutaneous syndrome and toxic epidermal necrolysis**: Oculomucocutaneous syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (Lyell syndrome) have been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discon-
Acute renal failure, nephrotic syndrome and interstitial nephritis: Acute renal failure, nephrotic syndrome and interstitial nephritis have been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately. ROXONIN should be used with special caution in such patients because hyperkalemia may appear in association with acute renal failure.

Cardiac failure congestive: Cardiac failure congestive has been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

Interstitial pneumonia: Interstitial pneumonia with manifestations of fever, cough, dyspnea, chest X-ray abnormalities, and eosinophilia have been reported with the use of ROXONIN. If these signs/findings are observed in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies such as corticosteroid medication, should be initiated immediately.

Gastrointestinal bleeding: Serious peptic ulceration or gastrointestinal bleeding from the small intestine and/or large intestine, e.g., hematemesis, melena and hematochezia, and consequent shock has been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

Gastrointestinal perforation: Gastrointestinal perforation has been reported with the use of ROXONIN. If epigastric pain, abdominal pain, etc. are noted in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

Hepatic function disorders, and jaundice: Hepatic function disorders including jaundice, increased serum levels of AST (GOT), ALT (GPT) and ã-GTP, or fulminant hepatitis have been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

Aseptic meningitis: Aseptic meningitis including fever, headache, nausea and vomiting, nuchal rigidity, clouding of consciousness, etc. has been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately. (in particular, the adverse event is likely to occur in the patients with systemic lupus erythematosus or mixed connective tissue disease).

Gastrointestinal perforation has been reported with the use of ROXONIN. If epigastric pain, abdominal pain, etc. are noted in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

Aplastic anemia: Aplastic anemia has been reported in association with the use of other non steroidal anti-inflammatory-analgesic drugs.

Acute renal failure, nephrotic syndrome and interstitial nephritis have been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

Gastrointestinal bleeding: Serious peptic ulceration or gastrointestinal bleeding from the small intestine and/or large intestine, e.g., hematemesis, melena and hematochezia, and consequent shock has been reported with the use of ROXONIN. Patients should be carefully monitored during treatment. If any abnormal symptoms occur in a patient being treated with ROXONIN, ROXONIN should be discontinued and appropriate therapies should be initiated immediately.

Aplastic anemia: Aplastic anemia has been reported in association with the use of other non steroidal anti-inflammatory-analgesic drugs.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

**General properties**

Loxoprofen sodium hydrate has excellent analgesic, anti-inflammatory and antipyretic properties, with particularly potent pain-relieving activity. This drug is a prodrug which, after being absorbed from the gut, is biotransformed into an active metabolite to exert its actions.

1. **Analgesic effect**
   
i) Loxoprofen sodium hydrate has been demonstrated to show an ED50 value of 0.13 mg/kg in the Randoll-Selitto test (inflamed paw pressing method: rat, p.o.), the analgesic effect being 10 to 20 times as potent as the reference drugs ketoprofen, naproxen and indomethacin.
   
   ii) As assessed using the rat thermal inflammatory pain test (rat, p.o.), loxoprofen sodium hydrate showed an ID50 value of 0.76 mg/kg and proved to be as potent as naproxen and 3 to >5 times more potent than ketoprofen and indomethacin.
   
   iii) In the chronic arthritis pain test (rat, p.o.), loxoprofen sodium hydrate produced the most profound analgesic effect (ED50: 0.53 mg/kg), 4 to 6 times more potent as compared with indomethacin, ketoprofen and naproxen.
   
   iv) The analgesic action of this drug is peripheral.

2. **Anti-inflammatory effect**

Loxoprofen sodium hydrate produces an anti-inflammatory effect essentially comparable with the effects of ketoprofen and naproxen on acute and chronic inflamations such as carrageenin-induced edema (rat) and adjuvant arthritis (rat).

3. **Antipyretic effect**

Loxoprofen sodium hydrate was demonstrated to exert an antipyretic effect, essentially comparable with the effects of ketoprofen and naproxen and about three times more potent than the effect of indomethacin on yeast-induced fever (rat).

4. **Mechanism of action**

Inhibition of prostaglandin biosynthesis constitutes the mechanism of action of this drug, the site of action being cyclo-oxygenase. When administered orally, loxoprofen sodium hydrate

(3) Other adverse reactions

<table>
<thead>
<tr>
<th>Frequency of Adverse Reactions</th>
<th>Incidence</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1 to &lt;1.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.05 to &lt;0.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;0.05%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence unknown</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Hypersensitivity**

<table>
<thead>
<tr>
<th>Rash</th>
<th>Note</th>
<th>Pruritus</th>
<th>Urticaria</th>
<th>Fever</th>
</tr>
</thead>
</table>

**Gastrointestinal**

<table>
<thead>
<tr>
<th>Abdominal pain Stomach discomfort Anorexia, Nausea and/ or vomiting, Diarrhea</th>
<th>Peptic ulcer</th>
<th>Constipation</th>
<th>Heartburn</th>
<th>Stomatitis</th>
<th>Dyspepsia</th>
<th>Thirst</th>
<th>Abdominal Distension</th>
</tr>
</thead>
</table>

**Cardiovascular**

<table>
<thead>
<tr>
<th>Palpitations</th>
<th>Blood pressure increased</th>
</tr>
</thead>
</table>

**Psychoneurologic**

<table>
<thead>
<tr>
<th>Sleepiness</th>
<th>Headache</th>
<th>Numbness</th>
</tr>
</thead>
</table>

**Hematologic**

<table>
<thead>
<tr>
<th>Anemia, Leukopenia Eosinophilia</th>
<th>Thrombocytopenia</th>
</tr>
</thead>
</table>

**Hepatic**

<table>
<thead>
<tr>
<th>Increased AST (GOT), increased ALT (GPT)</th>
<th>Increased ALP</th>
</tr>
</thead>
</table>

**Urinary**

<table>
<thead>
<tr>
<th>Hematuria Proteinuria</th>
</tr>
</thead>
</table>

**Others**

<table>
<thead>
<tr>
<th>Edema</th>
<th>Facial-warmth</th>
<th>Chest pain</th>
<th>Malaise</th>
</tr>
</thead>
</table>

Note: Discontinue administration.

4.9 Overdose

Although there is no experience of acute overdosing with loxoprofen sodium hydrate, it may be expected that the signs and symptoms mentioned under Adverse Reactions would be more pronounced.

There exists no specific antidote for loxoprofen sodium hydrate, overdose should be countered by conventional measures to reduce absorption (e.g., gastro-lavage and charcoal) and speed up elimination.

In the case of an actual or suspected overdose, patients should be observed and appropriate hydration maintained. Symptomatic and supportive treatments should be used.
is absorbed from the gastrointestinal tract as an unchanged compound with only a modest gastric-mucosal irritation. It is then rapidly biotransformed into the active metabolite trans-OH form (SRS coordination) with a potent inhibitory effect on prostaglandin biosynthesis to exert its pharmacologic effects.

5.2 Pharmacokinetic properties

Absorption and Metabolism

In sixteen healthy adult volunteers, ROXONIN tablets was absorbed rapidly following a single 60-mg oral dose, and loxoprofen (unchanged drug) and its trans-OH form (active metabolite) were demonstrated in blood. The time to peak plasma concentration was about 30 minutes for loxoprofen and about 50 minutes for the trans-OH form, with an approximate half-life of 1 hour and 15 minutes for both compounds.

Plasma concentrations following a single 60-mg dose of ROXONIN tablets (Simulation curves)

Drug-Metabolizing Enzymes

Looxoprofen sodium hydrate did not affect the metabolism of the various drugs that serve as the substrates for cytochrome P450 isoforms (CYP1A1/2, 2A6, 2B6, 2C8/9, 2C19, 2D6, 2E1, and 3A4), even at concentrations approximately 10 times as high as its peak plasma concentration (200 Î¼M) in a metabolic inhibition study with human liver microsomes in vitro.

<table>
<thead>
<tr>
<th>Pharmacokinetics Parameters (single dose)</th>
<th>Absorption rate constant (hr(^{-1}))</th>
<th>Elimination rate constant (hr(^{-1}))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Looxoprofen</td>
<td>11.21±1.82</td>
<td>λ(_1) = 4.04±0.93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>λ(_2) = 0.59±0.04</td>
</tr>
<tr>
<td>Trans-OH form</td>
<td>3.56±0.21</td>
<td>λ(_1) = 4.99±0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td>λ(_2) = 0.54±0.02</td>
</tr>
<tr>
<td></td>
<td>n=16. Mean±SE</td>
<td></td>
</tr>
</tbody>
</table>

(1) Absorption rate constant and elimination rate constant
(2) Plasma protein binding rate the plasma protein binding rate, as determined in humans (5 subjects at 1 hour after dosing of 60-mg ROXONIN tablets) was 97.0% and 92.8% for loxoprofen and the trans-OH compound, respectively.
(3) AUC (n=16, Mean±SE)

Loxoprofen: 6.70 ±0.26 μg.hr/mL
Trans-OH form: 2.02 ±0.05 μg.hr/mL

Excretion

ROXONIN is rapidly excreted in urine; it is excreted largely as glucuronate conjugates of loxoprofen and the trans-OH compound.

Excretion in urine after a single 60-mg dose of ROXONIN tablets
Absorption and Excretion Following Multiple Doses
Absorption and excretion of ROXONIN after oral administration at 80mg t.i.d. for 5 days in five healthy adult volunteers did not noticeably differ from those after a single oral dose; hence no evidence of accumulation.

5.3 Preclinical safety data
No safety information

6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Low Substituted Hydroxypropylcellulose, Red Ferric Oxide, Lactose hydrate, Magnesium Stearate

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
4 years

6.4 Special precautions for storage
Stored below 30°C.

6.5 Nature and contents of container
How supplied
Forming Aluminium / Aluminium blister pack.
Packs of 20 tablets

6.6 Special precautions for disposal and other handling
No special requirements.

7. Marketing Authorisation Holder
SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia

Under license from
Daiichi Sankyo Co. Ltd.
Tokyo-Japan

<table>
<thead>
<tr>
<th>Excretion in urine over 8 hours after dose (% of dose)</th>
<th>Free forms</th>
<th>Glucuronate conjugates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loxoprofen</td>
<td>2.07±0.29</td>
<td>21.0±0.4</td>
</tr>
<tr>
<td>Trans-OH form</td>
<td>2.21±0.47</td>
<td>16.0±0.6</td>
</tr>
</tbody>
</table>

n=6, Mean±SE

8. MARKETING AUTHORIZATION NUMBER
15/370/05

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
18/02/1426

10. DATE OF REVISION OF THE TEXT
June 2012

For any information, please contact
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
P.O. Box: 42600, Jeddah 21551, KSA
Tel: + 966 2 645 0303
Fax: + 966 2 6379997
www.sajapharma.com